Global Endometrial Cancer Market - Segmented By Type of Cancer, Therapy, Diagnosis Method, and Geography - Growth, Trends, and Forecast (2022 - 2030)

Detailed TOC of Global Endometrial Cancer Market - Segmented By Type of Cancer, Therapy, Diagnosis Method, and Geography - Growth, Trends, and Forecast (2022 - 2030)

1. Introduction
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porters Five Force Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Product and Services
5.2.5 Competitive Rivalry within the Industry
6. Drivers, Restraints, Opportunities and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 Rise in Awareness about Uterine Diseases and Their Available Therapies
6.1.2 Increasing Health Care Expenditure   
6.1.3 Innovation in Drug Development, and Subsequent Technological Advancements  
6.1.4 Growing of the Diagnostic Tests
6.2 Market Restraints
6.2.1 Low Success Rate in Clinical Trials for Cancer Drugs
6.2.2 High-Cost Associated with the Treatment  
6.2.3 Adverse Side-Effects of Treatment and High Toxicity of Drugs 
6.3 Opportunities
6.4 Key Challenges
7. Market Segmentation
7.1 By Type of Cancer
7.1.1 Endometrial Carcinoma
7.1.1.1 Adenocarcinoma
7.1.1.2 Carcinosarcoma
7.1.1.3 Squamous Cell Carcinoma
7.1.1.4 Others
7.1.2 Uterine sarcomas
7.2 By Type of Therapy
7.2.1 Surgery
7.2.2 Immunotherapy
7.2.3 Radiation Therapy
7.2.4 Chemotherapy
7.2.4.1 Paclitaxel (Taxol)
7.2.4.2 Carboplatin
7.2.4.3 Doxorubicin (Adriamycin) or Liposomal Doxorubicin (Doxil)
7.2.4.4 Cisplatin
7.2.4.5 Others
7.2.5 Follow-Up Treatment
7.2.6 Others
7.3 By Diagnosis Method
7.3.1 Biopsy
7.3.2 Pelvic Ultrasound
7.3.3 Hysteroscopy
7.3.4 Dilation and Curettage
7.3.5 CT Scan
7.3.6 Others
7.4 By Geography
7.4.1 North America
7.4.1.1 United States
7.4.1.2 Canada
7.4.1.3 Mexico
7.4.2 Europe
7.4.2.1 France
7.4.2.2 Germany
7.4.2.3 United Kingdom
7.4.2.4 Italy
7.4.2.5 Spain
7.4.2.6 Rest of Europe
7.4.3 Asia-Pacific
7.4.3.1 China
7.4.3.2 Japan
7.4.3.3 India
7.4.3.4 Australia & New Zealand
7.4.3.5 South Korea
7.4.3.6 Rest of Asia-Pacific
7.4.4 Middle East & Africa
7.4.4.1 GCC
7.4.4.2 South Africa
7.4.4.3 Rest of the Middle East & Africa
7.4.5 South America
7.4.5.1 Brazil
7.4.5.2 Argentina
7.4.5.3 Rest of South America
8. Competitive Landscape
8.1 Mergers & Acquisition Analysis
8.2 Agreements, Collaborations and Partnerships
8.3 New Products Launches
9. Key Players
9.1 Ariad Pharmaceuticals
9.2 Abbott Laboratories
9.3 Becton, Dickinson & Co.
9.4 GlaxoSmithKline
9.5 Merck
9.6 Novartis AG
9.7 Sanofi
9.8 Siemens Healthcare
9.9 Roche
9.10 List Not Exhaustive
10. Future of the Market